Drug intelligence / Profile preview

ter-101

Development stage: Phase 2
Lead developer: Teres Bio
Modality: Small Molecules
Administration: Topical

Overview

TER-101 is a topical ointment developed for the treatment of atopic dermatitis. It was evaluated in a Phase 2 clinical trial that assessed its efficacy, safety, and tolerability when applied twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis. The trial was completed, but detailed results are not publicly available.

Targets

FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on ter-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ter-101.

Explore the full profile